XML 60 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Party Transactions - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Related Party Transaction [Line Items]          
Research and development expense [1] $ 17,845,000 $ 12,052,000 $ 49,770,000 $ 26,666,000  
Accounts receivable, related party amount, current 1,133,000   1,133,000   $ 752,000
Other current assets, related party amount 583,000   583,000   0
Deferred revenue related party amount 171,000   171,000   527,000
Casebia Therapeutics LLP [Member]          
Related Party Transaction [Line Items]          
Revenue from collaboration agreement 1,200,000 400,000 3,900,000 400,000  
Research and development expense 1,200,000 400,000 3,700,000 400,000  
Bayer Healthcare LLC [Member]          
Related Party Transaction [Line Items]          
Sublicense fees payable 0   0   500,000
Bayer Healthcare LLC [Member] | Casebia Therapeutics LLP [Member]          
Related Party Transaction [Line Items]          
Revenue from collaboration agreement 1,200,000 400,000 3,900,000 400,000  
Research and development expense 1,200,000 400,000 3,700,000 400,000  
Research and development expenses reimbursed 900,000   1,600,000    
Accounts receivable, related party amount, current 1,100,000   1,100,000   800,000
Other current assets, related party amount 600,000   600,000   0
Deferred revenue related party amount 200,000   200,000   $ 500,000
Bayer Healthcare LLC [Member] | Research and Development [Member]          
Related Party Transaction [Line Items]          
Sublicense fees recorded $ 0 $ 17,000 $ 0 $ 1,000,000  
[1] Including the following research and development expense with a related party, See Note 11: